Similar articles

Abstract: Objective: The influence of hormone replacement therapy (HRT) on hemostasis processes depends on the type of hormone, the combination of doses, the time of taking HRT, and the route of administration (oral, transdermal, implanted). The aim of the current study was to assess some parameters of coagulation, especially tissue factor pathway inhibitor (TFPI) and tissue factor (TF) in postmenopausal women using oral or transdermal HRT. Methods: The study was conducted on 76 healthy women, including 46 women aged 44–58 years who were taking oral (26) or transdermal (20) HRT, and 30 women aged 44–54 years who did not take HRT as the control group. Plasma concentrations of TF, TFPI, thrombin-antithrombin complex (TAT), and D-dimer were performed by enzyme-linked immunosorbent assay (ELISA). Moreover, the concentration of fibrinogen and activity of protein C were measured by chromogenic and chronometric methods. Results: We observed a significantly higher concentration of TF and a significantly lower concentration of TFPI in women taking oral and transdermal HRT in comparison with the control group. We also found a significantly lower concentration of fibrinogen in women taking oral HRT vs. the control group. Moreover, no statistically significant changes in concentrations of TAT and D-dimer, or activity of protein C were noted. Conclusions: In this study, the occurrence of an increased TF concentration simultaneously with a decreased concentration of TFPI in women taking HRT indicates hypercoagulability. No significant modification of TAT or D-dimer occurred, and thus there may not be increased risk of thrombosis.

[1]Andersen, L.F., Gram, J., Skouby, S.O., Jespersen, J., 1999. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am. J. Obstet. Gynecol., 180(2):283-289.

[2]Bajaj, M.S., Birktoft, J.J., Steer, S.A., Bajaj, S.P., 2001. Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost., 86(4):959-972.

[3]Bladbjerg, E.M., Skouby, S.O., Andersen, L.F., Jespersen, J., 2002. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum. Reprod., 17(12):3235-3241.

[4]Bladbjerg, E.M., Madsen, J.S., Kristensen, S.R., Abrahamsen, B., Brixen, K., Mosekilde, L., Jespersen, J., 2003. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J. Thromb. Haemost., 1(6):1208-1214.

[5]Callejon, D.R., Franceschini, S.A., Montes, M.B., Toloi, M.R., 2005. Hormone replacement therapy and hemostasis. Effects in Brazilian postmenopausal women. Maturitas, 52(3-4):249-255.

[6]Dębski, R., 2006. The hormone replacement therapy and the diseases of the arteries. Przegl. Menopauz., 5:274-279 (in Polish).

[7]Gomes, M.P., Deitcher, S.R., 2004. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. A clinical review. Arch. Intern. Med., 164(18):1965-1976.

[8]Gracia, C.R., Sammel, M.D., Frejman, E.W., Lin, H., Langan, E., Kapoor, S., Nelson, D.B., 2005. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause, 12(2):128-135.

[9]Guimarães, D.A.M., das Graças Carvalho, M., Cardoso, J., de Oliveira Sousa, M., Franco, R.M., de Almeida Franco, H., Alvim, T.C., da Silva Teixeira, G., Sant′Ana Dusse, L.M., Fernandes, A.P., 2009. Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy. J. Thromb. Thrombolysis., 27(2):135-140.

[10]Hale, G.E., Zhao, X., Hughes, C.L., Burger, H.G., Robertson, D.M., Fraser, I.S., 2007. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the staging of reproductive aging workshop (STRAW) staging system. J. Clin. Endocrinol. Metab., 92(8):3060-3067.

[11]Harris, G.M., Stendt, C.L., Vollenhoven, B.J., Gan, T.E., Tipping, P.G., 1999. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am. J. Hematol., 60(3):175-180.

[12]Høibraaten, E., Os, I., Selijeflot, I., Andersen, T.O., Hofstad, A., Sandset, P.M., 2000. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. Throm. Res., 98(1):19-27.

[13]Iacoviello, L., Vischetti, M., Zito, F., Benedetta Donati, M., 2001. Gene encoding fibrinogen and cardiovascular risk. Hypertension, 38(5):1199-1203.

[14]Koh, K.K., Jin, D.K., Yang, S.H., Lee, S.K., Hwang, H.Y., Kang, M.H., Kim, W., Kim, D.S., Choi, I.S., Shin, E.K., 2001. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation, 103(15):1961-1966.

[15]Koh, K.K., Ahn, J.Y., Kim, D.S., Han, S.H., Shin, M.S., Ryu, W.S., Park, G.S., Ahn, T.H., Choi, I.S., Shin, E.K., 2003. Effect of hormone replacement therapy on tissue factor activity, C-reactive protein, and the tissue factor pathway inhibitor. Am. J. Cardiol., 91(3):371-373.

[16]LaCroix, A.Z., 2005. Estrogen with and without progestin: benefits and risks of short-term use. Am. J. Med., 118(12):79-87.

[17]Luyer, M.D., Khosla, S., Owen, W.G., Miller, V.M., 2001. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J. Clin. Endocr. Metab., 86(8):3629-3634.

[18]Peverill, R.E., 2003. Hormone therapy and venous thromboembolism. Best Pract. Res. Clin. Endocrinol. Metab., 17(1):149-164.

[19]Peverill, R.E., Teede, H.J., Smolich, J.J., Malan, E., Kotsopoulos, D., Tipping, P.G., McGrath, B.P., 2001. Effects of combined oral hormone replacement therapy on tissue factor inhibitor pathway and factor VII. Clin. Sci., 101(1):93-99.

[20]Post, M.S., van der Mooren, M.J., van Baal, W.M., Blankenstein, M.A., Merkus, H.M., Kroeks, M.V., Franke, H.R., Kenemans, P., Stehouwer, C.D., 2003. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am. J. Obstet. Gynecol., 189(5):1221-1227.

[21]Ruszkowska, B., Manysiak, S., Małecka, B., Dymek, G., Rość, D., Odrowąż-Sypniewka, G., 2010. Parameters of fibrinolysis in postmenopausal women taking oral and transdermal hormone replacement therapy. Adv. Clin. Exp. Med., 19(2):203-210.

[22]Stevenson, J.C., 2009. HRT and cardiovascular disease. Best Pract. Res. Clin. Obstet. Gynaecol., 23(1):109-120.

[23]The Writing Group for the PEPI Trial, 1995. Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women. JAMA, 273(3):199-208.

[24]Versteeg, H.H., Peppelenbosch, M.P., Spek, C.A., 2001. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signaling? Thromb. Haemost., 86(6):1353-1359.

[25]WHO (World Health Organization), 1996. Research on the Menopause in the 1990s: Report of a WHO Scientific Group. WHO Technical Report Series 866. Geneva, p.1-107.